PL2053048T3 - Chemiczny sposób sulfonowania in situ - Google Patents

Chemiczny sposób sulfonowania in situ

Info

Publication number
PL2053048T3
PL2053048T3 PL09152654T PL09152654T PL2053048T3 PL 2053048 T3 PL2053048 T3 PL 2053048T3 PL 09152654 T PL09152654 T PL 09152654T PL 09152654 T PL09152654 T PL 09152654T PL 2053048 T3 PL2053048 T3 PL 2053048T3
Authority
PL
Poland
Prior art keywords
sulphonating
situ
chemical
sulphonating process
situ sulphonating
Prior art date
Application number
PL09152654T
Other languages
English (en)
Inventor
Jörgen BLIXT
Michael David Golden
Philip John Hogan
David Michael Glanville Martin
Francis Joseph Montgomery
Zakariya Patel
John David Pittman
George Joseph Sependa
Christopher John Squire
Nicholas Cartwright Alexander Wright
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35395001&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2053048(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of PL2053048T3 publication Critical patent/PL2053048T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/16—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with acylated ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
PL09152654T 2005-09-30 2006-09-27 Chemiczny sposób sulfonowania in situ PL2053048T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0519879.1A GB0519879D0 (en) 2005-09-30 2005-09-30 Chemical process
EP09152654A EP2053048B8 (en) 2005-09-30 2006-09-27 Chemical in situ sulphonating process
EP06794582A EP1943240B1 (en) 2005-09-30 2006-09-27 Chemical process

Publications (1)

Publication Number Publication Date
PL2053048T3 true PL2053048T3 (pl) 2011-03-31

Family

ID=35395001

Family Applications (2)

Application Number Title Priority Date Filing Date
PL06794582T PL1943240T3 (pl) 2005-09-30 2006-09-27 Proces chemiczny
PL09152654T PL2053048T3 (pl) 2005-09-30 2006-09-27 Chemiczny sposób sulfonowania in situ

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL06794582T PL1943240T3 (pl) 2005-09-30 2006-09-27 Proces chemiczny

Country Status (31)

Country Link
US (8) US8163926B2 (pl)
EP (2) EP2053048B8 (pl)
JP (2) JP5213715B2 (pl)
KR (1) KR101307641B1 (pl)
CN (3) CN102503933B (pl)
AR (1) AR055671A1 (pl)
AT (2) ATE481399T1 (pl)
AU (1) AU2006296367B2 (pl)
BR (1) BRPI0616715A2 (pl)
CA (2) CA2745829C (pl)
CY (2) CY1110275T1 (pl)
DE (2) DE602006010428D1 (pl)
DK (2) DK2053048T3 (pl)
ES (2) ES2350513T3 (pl)
GB (1) GB0519879D0 (pl)
HR (2) HRP20100019T1 (pl)
IL (2) IL190172A (pl)
ME (2) ME01531B (pl)
MY (2) MY145540A (pl)
NO (1) NO342152B1 (pl)
NZ (2) NZ593930A (pl)
PL (2) PL1943240T3 (pl)
PT (2) PT2053048E (pl)
RS (2) RS51263B (pl)
RU (1) RU2448102C2 (pl)
SG (1) SG165416A1 (pl)
SI (2) SI2053048T1 (pl)
TW (2) TWI424991B (pl)
UY (1) UY29824A1 (pl)
WO (1) WO2007036713A2 (pl)
ZA (1) ZA200802416B (pl)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1474420T3 (da) * 2002-02-01 2012-05-21 Astrazeneca Ab Quinazolinforbindelser
GB0519879D0 (en) * 2005-09-30 2005-11-09 Astrazeneca Ab Chemical process
CL2007003158A1 (es) * 2006-11-02 2008-05-16 Astrazeneca Ab Procedimiento de preparacion de compuestos derivados de quinazolina o sus sales farmaceuticamente aceptables; compuestos intermediarios; procedimiento de preparacion.
ES2547902T3 (es) * 2011-09-01 2015-10-09 Symrise Ag Procedimiento para la preparación de derivados de indanona
ES2893473T3 (es) * 2012-08-15 2022-02-09 Glaxo Group Ltd Proceso químico
CN104098544A (zh) * 2013-04-07 2014-10-15 浙江九洲药物科技有限公司 一种凡德他尼的制备方法
CN106397401B (zh) * 2016-08-30 2018-11-13 山东罗欣药业集团股份有限公司 一种抗癌药物的晶体化合物及其制备方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4870083A (en) * 1987-11-24 1989-09-26 Merrell Dow Pharmaceuticals Inc. 1,4-Disubstituted-piperidinyl compounds useful as analgesics and muscle relaxants
JP2829744B2 (ja) 1989-05-31 1998-12-02 川研ファインケミカル株式会社 ピペリジンカルボン酸類の製造方法
WO1992006086A1 (en) 1990-10-01 1992-04-16 Janssen Pharmaceutica N.V. Novel 4-piperidinylcarbonyl derivatives
AU658194B2 (en) 1991-03-28 1995-04-06 Eisai Co. Ltd. Heterocyclic-cyclic amine derivatives
AU658646B2 (en) 1991-05-10 1995-04-27 Rhone-Poulenc Rorer International (Holdings) Inc. Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5710158A (en) 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
CA2118117A1 (en) 1993-02-18 1994-08-19 Shigeki Fujiwara Adenosine uptake inhibitor
AU680004B2 (en) 1993-05-26 1997-07-17 Syntex (U.S.A.) Inc. Novel 1-phenylalkanone 5-HT4 receptor ligands
DE4326344A1 (de) 1993-08-05 1995-02-09 Thomae Gmbh Dr K Carbonamide, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
ATE170174T1 (de) * 1994-01-13 1998-09-15 Merck Sharp & Dohme Gem-bissubstituierte azazyclische tachykinin- antagonisten
GB9624482D0 (en) * 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
ATE211134T1 (de) 1996-03-05 2002-01-15 4-anilinochinazolin derivate
WO1998010767A2 (en) 1996-09-13 1998-03-19 Sugen, Inc. Use of quinazoline derivatives for the manufacture of a medicament in the treatment of hyperproliferative skin disorders
GB9718972D0 (en) * 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
PL203782B1 (pl) * 1999-11-05 2009-11-30 Astrazeneca Ab Pochodne chinazoliny,sposoby ich wytwarzania,ich kompozycje farmaceutyczne oraz ich zastosowania
GB0126879D0 (en) 2001-11-08 2002-01-02 Astrazeneca Ab Combination therapy
AU2002366801B8 (en) 2001-12-20 2009-05-21 Osi Pharmaceuticals, Inc. Pyrrolopyrimidine A2b selective antagonist compounds, their synthesis and use
DK1474420T3 (da) 2002-02-01 2012-05-21 Astrazeneca Ab Quinazolinforbindelser
JP4389205B2 (ja) 2002-02-06 2009-12-24 宇部興産株式会社 ４−アミノキナゾリン化合物の製法
GB0218526D0 (en) 2002-08-09 2002-09-18 Astrazeneca Ab Combination therapy
WO2004014383A1 (en) 2002-08-09 2004-02-19 Astrazeneca Ab Combination of zd6474, an inhibitor of the vascular endothelial growth factor receptor, with radiotherapy in the treatment of cancer
GB0223380D0 (en) 2002-10-09 2002-11-13 Astrazeneca Ab Combination therapy
ATE506062T1 (de) 2003-02-13 2011-05-15 Astrazeneca Ab Kombinationstherapie von zd6474 mit 5-fu oder/und cpt-11
EP1648465B1 (en) 2003-07-10 2010-08-25 AstraZeneca AB Use of the quinazoline derivative zd6474 combined with platinum compounds and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability
GB0318423D0 (en) 2003-08-06 2003-09-10 Astrazeneca Ab Chemical compounds
GB0519879D0 (en) * 2005-09-30 2005-11-09 Astrazeneca Ab Chemical process

Also Published As

Publication number Publication date
DE602006010428D1 (de) 2009-12-24
AR055671A1 (es) 2007-08-29
CA2745829C (en) 2013-07-02
ZA200802416B (en) 2009-01-28
HK1130478A1 (en) 2009-12-31
IL190172A0 (en) 2008-08-07
ME01531B (me) 2014-04-20
WO2007036713A3 (en) 2007-06-14
HRP20100620T1 (hr) 2010-12-31
US10344015B2 (en) 2019-07-09
JP5213715B2 (ja) 2013-06-19
DK1943240T3 (da) 2010-03-01
US20220033377A1 (en) 2022-02-03
UY29824A1 (es) 2007-04-30
ATE481399T1 (de) 2010-10-15
CY1110275T1 (el) 2015-01-14
TW201018660A (en) 2010-05-16
CN102503933B (zh) 2014-06-25
CN101277948B (zh) 2013-03-13
SI1943240T1 (sl) 2010-02-26
HRP20100019T1 (hr) 2010-02-28
NZ566566A (en) 2011-08-26
TWI424991B (zh) 2014-02-01
SI2053048T1 (sl) 2010-12-31
KR20080049114A (ko) 2008-06-03
SG165416A1 (en) 2010-10-28
US20240150317A1 (en) 2024-05-09
NO20081267L (no) 2008-04-30
IL190172A (en) 2014-05-28
EP1943240A2 (en) 2008-07-16
ATE448218T1 (de) 2009-11-15
ES2335435T3 (es) 2010-03-26
IL227574A (en) 2015-08-31
EP2053048A1 (en) 2009-04-29
US8865899B2 (en) 2014-10-21
EP2053048B1 (en) 2010-09-15
CN102503898B (zh) 2015-03-25
AU2006296367A1 (en) 2007-04-05
RU2448102C2 (ru) 2012-04-20
US9815816B2 (en) 2017-11-14
DK2053048T3 (da) 2010-11-29
JP2009510039A (ja) 2009-03-12
US20120095229A1 (en) 2012-04-19
NO342152B1 (no) 2018-04-03
PT2053048E (pt) 2010-11-10
US20190263782A1 (en) 2019-08-29
CN102503898A (zh) 2012-06-20
EP1943240B1 (en) 2009-11-11
KR101307641B1 (ko) 2013-09-12
TW200745036A (en) 2007-12-16
RS51515B (sr) 2011-06-30
NZ593930A (en) 2013-02-22
PL1943240T3 (pl) 2010-04-30
MY145540A (en) 2012-02-29
US8163926B2 (en) 2012-04-24
US20180118716A1 (en) 2018-05-03
AU2006296367B2 (en) 2011-08-11
CA2624045C (en) 2012-05-22
JP2013063998A (ja) 2013-04-11
CN102503933A (zh) 2012-06-20
CA2624045A1 (en) 2007-04-05
CA2745829A1 (en) 2007-04-05
RU2008116573A (ru) 2009-11-10
PT1943240E (pt) 2010-01-11
GB0519879D0 (en) 2005-11-09
US20090203905A1 (en) 2009-08-13
BRPI0616715A2 (pt) 2011-06-28
HK1122553A1 (en) 2009-05-22
ME01466B (me) 2014-04-20
RS51263B (sr) 2010-12-31
US20160185754A1 (en) 2016-06-30
US20140378684A1 (en) 2014-12-25
TWI328580B (en) 2010-08-11
MY149834A (en) 2013-10-31
CN101277948A (zh) 2008-10-01
JP5654546B2 (ja) 2015-01-14
CY1110887T1 (el) 2015-06-10
WO2007036713A2 (en) 2007-04-05
DE602006017004D1 (de) 2010-10-28
EP2053048B8 (en) 2011-09-21
ES2350513T3 (es) 2011-01-24

Similar Documents

Publication Publication Date Title
IL208667A0 (en) Chemical process
GB0514078D0 (en) Chemical process
GB0428328D0 (en) Chemical process
GB0426057D0 (en) Chemical process
GB0501730D0 (en) Process
ZA200802416B (en) Chemical process
GB0522061D0 (en) Chemical process
TWI366562B (en) Chemical process
GB0403744D0 (en) Chemical process
GB0427697D0 (en) Chemical process
GB0426059D0 (en) Chemical process
GB0501349D0 (en) Process
GB0501102D0 (en) Process
GB0411596D0 (en) Chemical process
EP1915131A4 (en) PROCESS
GB0515926D0 (en) Chemical process
GB0517051D0 (en) Chemical process
GB0501254D0 (en) Process
GB0501100D0 (en) Process
GB0428103D0 (en) Chemical Process
GB0514086D0 (en) Chemical process
GB0514137D0 (en) Chemical process
GB0522431D0 (en) Chemical process
GB0502963D0 (en) Chemical process
GB0517413D0 (en) Chemical process